Empagliflozin (EMPA), a sodium‐glucose cotransporter 2 (SGLT2) inhibitor used for diabetes mellitus type II therapy, has demonstrated a beneficial role in improving cardiovascular outcomes for patients with heart failure. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.